How many 8-K filings has Protara Therapeutics, Inc. filed?

Protara Therapeutics, Inc. (TARA) has 13 8-K (Current Event Report) filings on record, spanning Mar 2024 to Dec 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Protara Therapeutics, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Protara Therapeutics, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Protara Therapeutics, Inc. (TARA) — 8-K Filings

All 8-K filings from Protara Therapeutics, Inc.. Browse 13 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (13)

8-K Filing — Dec 15, 2025
8-K Filing — Dec 8, 2025
8-K Filing — Dec 3, 2025
8-K Filing — Nov 19, 2025
Protara Therapeutics Files 8-K on Shareholder Vote Matters — Jun 12, 2025 Risk: medium
Protara Therapeutics, Inc. filed an 8-K on June 12, 2025, reporting on matters submitted to a vote of its security holders as of June 11, 2025. The filing indic
8-K Filing — Apr 28, 2025
Protara Therapeutics Files 8-K — Jan 13, 2025 Risk: low
Protara Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting on events including Regulation FD disclosures, other events, and financial statements. Th
Protara Therapeutics Files 8-K: Material Agreement — Dec 11, 2024 Risk: medium
On December 9, 2024, Protara Therapeutics, Inc. entered into a material definitive agreement. The filing also includes Regulation FD Disclosure and Financial St
Protara Therapeutics Files 8-K with Financials — Dec 5, 2024 Risk: low
On December 5, 2024, Protara Therapeutics, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Other Events. The filing also includes financial st
Protara Therapeutics Files 8-K with Financial Updates — Aug 6, 2024 Risk: medium
On August 6, 2024, Protara Therapeutics, Inc. filed an 8-K report detailing its financial results and operations. The filing includes financial statements and e
Protara Therapeutics Files 8-K on Shareholder Matters — Jun 10, 2024 Risk: low
Protara Therapeutics, Inc. filed an 8-K on June 10, 2024, reporting on matters submitted to a vote of security holders as of June 7, 2024. The filing details th
Protara Therapeutics Files 8-K: Material Agreement & Equity Sales — Apr 5, 2024 Risk: medium
On April 5, 2024, Protara Therapeutics, Inc. announced an entry into a material definitive agreement. The company also disclosed unregistered sales of equity se
Protara Therapeutics Appoints New Chief Medical Officer — Mar 18, 2024 Risk: medium
Protara Therapeutics, Inc. announced on March 18, 2024, the appointment of Dr. Jonathan G. T. Feeney as Chief Medical Officer. Dr. Feeney previously served as C

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX